




**Asiatic Laboratories Limited**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
For the Period from 1st July 2024 to 30 September 2024


Particulars	Notes	Amount in Taka	
		30 September 2024	30 September 2023
Net Sales Revenue	27.00	264,807,299	321,895,210
Less: Cost of Goods Sold	28.00	(154,773,897)	(187,994,908)
<b>Gross Profit</b>		<b>110,033,402</b>	<b>133,900,302</b>
Less: Operating Expenses	29.00	(59,539,934)	(53,245,861)
<b>Profit from Operation</b>		<b>50,493,468</b>	<b>80,654,441</b>
Other Income	30.00	-	-
Financial Expenses	31.00	(9,756,401)	(10,877,261)
Interest on Lease Liability	32.00	(285,145)	(256,663)
<b>Profit Before WPPF &amp; Income Tax</b>		<b>40,451,922</b>	<b>69,520,517</b>
Less: Workers' Profit Participation Fund Expenses		(1,926,282)	(3,310,501)
<b>Profit Before Income Tax</b>		<b>38,525,640</b>	<b>66,210,016</b>
<b>Income Tax Expenses</b>		<b>(8,901,868)</b>	<b>22,253,351</b>
Current Tax	22.00	(5,076,997)	(13,809,142)
Deferred Tax Income/(Expense)	19.00	(3,824,871)	36,062,492
<b>Net Profit After Income Tax</b>		<b>29,623,772</b>	<b>88,463,367</b>
<b>Add: Other Comprehensive Income:</b>		<b>233,598</b>	<b>246,232</b>
Revaluation surplus during the year		-	-
Add: Deferred Tax (expenses)/income on Revaluation surplus		-	-
Adjustment of deferred tax on depreciation for Revaluation Surplus		233,598	246,232
<b>Total Comprehensive Income for the year</b>		<b>29,857,371</b>	<b>88,709,598</b>
<b>Earnings Per Share (EPS)</b>	34.00	<b>0.24</b>	<b>0.92</b>
<b>Number of share considered for calculating EPS</b>		<b>122,393,455</b>	<b>96,484,364</b>


*The annexed notes form an integral part of these Financial Statements.*

  
**Chief Financial Officer**

  
**Company Secretary**

  
**Director**

  
**Managing Director**

  
**Chairman**

Signed in terms of our separate report of even date annexed.

Place: Dhaka

Dated: 30 November 2024